595021 Provided is the use of an active compound which is a calcitonin family member other than amylin, a modified calcitonin family member with more than 75% identity, other than a modified amylin, or a calcitonin receptor agonist in the manufacture of a pharmaceutical formulation adapted for enteral administration for treating type I diabetes, type II diabetes, or metabolic syndrome, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level. The active compound be a calcitonin, e.g. from salmon.
